Christopher R. Cline, CHIEF FINANCIAL OFFICER at Travere Therapeutics, Inc. (TVTX), sold 1,745 shares at $32.90 ($56K) on 2026-02-04, disclosed to the SEC on 2026-02-05.
Scheduled sale ($56k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.14 | 1,635 | $53K | 93.6% |
| 2 | $32.90 | 110 | $4K | 6.4% |
| Total | $32.19 avg | 1,745 | $56K | 100% |
| Filing → |
| TVTX | SELL | 2026-05-06 | $115K | — | Filing → |
| TVTX | SELL | 2026-04-15 | $349K | — | Filing → |
| TVTX | SELL | 2026-02-03 | $233K | — | Filing → |